[ad_1]
Following the death of a 49-year-old nurse from the Zwettl state hospital, who had previously been administered a Covid-19 vaccine from AstraZeneca, the vaccine will continue to be used in Lower Austria. The vaccines with the batch in question, number ABV 5300, were suspended by the federal government and the remaining stocks are no longer issued. All other lots will continue to be used.
AGES has established a hotline for all people who have been vaccinated with the ABV 5300 vaccine and have questions about it: Tel. 0800 555 621.
The Vienna General Hospital, where the 49-year-old woman’s body is autopsied, and the Federal Office for Health Security (BASG) have so far been unable to establish a connection between the woman’s death and the vaccine.
Nothing has changed in the approval of the vaccine, Stefan Spielbichler from the Lower Austrian emergency number said yesterday: “We are guided by AGES (Agency for Health and Food Safety, Note) and we cannot make an unauthorized decision here.”
Over the weekend there were two reports related to a vaccination from the same batch at the Zwettl Clinic: The 49-year-old man died of a severe bleeding disorder. A 35-year-old colleague who had developed a pulmonary embolism is recovering at Klinikum Zwettl.
No criminal proceedings have been planned
The 49-year-old man was taken to the intensive care unit of the Vienna General Hospital a week ago and died the next day. She had received the first vaccine ten days before being admitted to Zwettl State Hospital. There is currently no indication that the vaccine was the trigger for the bleeding disorder, but due to the coincidence of the timing, the Vienna General Hospital and MedUni Vienna would do their best to fully clarify the cause of death, he said yesterday. The exams would take another two weeks.
“According to the information so far, there is no evidence of criminal guilt, we do not intend to initiate that process at the moment,” the Krems prosecutor said yesterday in response to a request from OÖN.
“Thrombotic events are not among the known side effects of the AstraZeneca vaccine,” explained the BASG. The clinical data did not reveal any worrisome data compared to a placebo. The international analysis of side effect reports that began immediately did not result in a backlog of similar case reports. “We would like to see how the unfortunate event could happen as soon as possible,” said AstraZeneca. The vaccine was approved by the European Medicines Agency and WHO on the basis of a global clinical program with 23,000 participants. (kri)
